XNAS · Healthcare · Biotechnology
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-02-27 | Q4 2025 | -1.60 | -0.45 | +71.88% | $0 | ✅ Beat | -0.99% | +14.32% | -6.59% |
| 2025-11-17 | Q3 2025 | -0.32 | -0.13 | +59.38% | $0 | ✅ Beat | — | — | — |
| 2025-08-15 |
| Q2 2025 |
| — |
| -0.19 |
| — |
| $0 |
| — |
| -4.34% |
| +2.19% |
| +3.41% |
| 2025-03-21 | Q4 2024 | — | -0.04 | — | $0 | — | -3.88% | -5.83% | -15.53% |
| 2024-11-15 | Q3 2024 | — | -0.20 | — | $0 | — | -4.15% | -5.26% | -6.03% |
| 2024-08-14 | Q2 2024 | — | 0.06 | — | $0 | — | +1.71% | -4.78% | +20.82% |
| 2024-05-10 | Q4 2023 | -0.44 | 1.36 | +409.09% | $0 | ✅ Beat | -0.40% | -0.80% | -13.10% |
| 2023-11-16 | Q3 2023 | -0.19 | -0.67 | -252.63% | $0 | ❌ Miss | +30.43% | +26.96% | +1.74% |
Showing last 8 quarters.